Establishment and evaluation of a prognostic model for patients with unresectable gastric cancer liver metastases

Table 1 Demographic and clinical characteristics of the derivation and validation cohorts, n (%)/median (25^th, 75^th)

Variables	Derivation cohort	Validation cohort	P value
n	248	124
Age (yr)	60.0 (52-67)	60.0 (53-67)	0.198
Sex			0.427
Men	204 (82.3)	102 (82.3)	0.219
Women	44 (17.7)	22 (17.7)	0.274
BMI, kg/m2	23.6 (21.1-25.7)	23.6 (20.9-25.8)	0.295
Albumin, g/L	36.2 (33.5-40.0)	36.4 (33.6-40.3)	0.187
Hemoglobin, g/L	117.0 (95-135.3)	117.0 (95-135)	0.109
CEA, ng/mL	9.7 (2.5-59.3)	9.6 (2.4-59)	0.159
AFP, μg/L	3.5 (2.2-8.2)	3.4 (2.2-8.)	0.213
ALT, U/L	18.6 (11.8-35.2)	18.7 (11.9-35.4)	0.308
AST, U/L	22.8 (15.4-47.9)	22.7 (15.4-47.7)	0.103
GGT, U/L	22.5 (10.3-46.2)	22.4 (10.3-46.0)	0.235
TG, mmol/L	1.1 (0.9-1.4)	1.1 (0.9-1.4)	0.122
TC, mmol/L	4.2 (3.5-4.8)	4.2 (3.4-4.8)	0.169
Drinking habit			0.155
Yes	91 (36.8)	46 (37)
No	157 (63.2)	78 (63)
Primary tumor size, cm	3.4 (2.4-5)	3.4 (2.5-5)	0.213
Surgery			0.409
Yes	64 (25.9)	32 (25.8)
No	184 (74.1)	92 (74.2)
Extrahepatic metastases			0.504
Yes	48 (19.4)	24 (19.4)
No	200 (80.6)	100 (80.6)
Chemotherapy			0.306
Yes	40 (16.1)	20 (16.1)
No	208 (83.9)	104 (83.9)
Primary site			0.186
Proximal	60 (24.2)	30 (24.2)
Gastric body	75 (30.3)	37 (29.8)
Distal	101 (40.7)	51 (41.1)
Multiple or whole stomach/anastomosis	12 (4.8)	6 (4.8)
Metastases size (max)	3.3 (2.2-5.7)	3.3 (2.2-5.6)	0.279
Metastases site			0.127
Left liver	24 (9.6)	12 (9.6)
Right liver	39 (15.7)	19 (15.3)
Whole liver	182 (73.4)	91 (73.4)
Hilar	2 (0.9)	1 (0.9)
Other	1 (0.4)	1 (0.8)

Data expressed as median (25^th, 75^th) for skewed variables and percentage (%) for categorical variables. BMI: Body mass index; CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein; TC: Total cholesterol; TG: Triglyceride; AST: Aspartate transferase; GGT: Gamma-glutamyl transferase; ALT: Alanine aminotransferase.